Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Supernus Pharmaceuticals, Inc. (SUPN) stock forecast summary
On Oct. 16, 2026, SUPN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5121 stocks scored that day.
Supernus Pharmaceuticals, Inc. is a mid-cap company with a market capitalization of $2.30B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For SUPN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.4%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SUPN included.
Follow SUPN freeSUPN price chart and AI forecast
How SUPN ranks among 5121 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Supernus Pharmaceuticals, Inc. (SUPN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | SUPN | Rank |
|---|---|---|
| Market Cap | $2.30B | 60/60 |
| P/B Ratio | 2.23x | 39/42 |
| EPS | $-2.09 | – |
| Book Value/Share | $17.74 | – |
| Revenue/Share | $14.29 | – |
| FCF/Share | $0.32 | – |
Profitability & Margins
| Metric | SUPN | Rank |
|---|---|---|
| ROE | -10.7% | 25/38 |
| ROA | -7.7% | 28/42 |
| ROIC | -12.1% | 28/45 |
| Gross Margin | 88.1% | 10/35 |
| Operating Margin | -15.7% | 26/38 |
| Net Margin | -13.2% | 24/34 |
| EBT Margin | -14.9% | 33/45 |
| Tax Rate | 11.0% | – |
Financial Health
| Metric | SUPN | Rank |
|---|---|---|
| Current Ratio | 2.08x | 37/58 |
| Quick Ratio | 1.77x | 21/43 |
| D/E Ratio | 0.38x | 32/48 |
| Financial Leverage | 1.38x | 31/48 |
| Interest Coverage | -19.3x | 28/35 |
| Working Capital | $376M | 45/58 |
Cash Flow
| Metric | SUPN | Rank |
|---|---|---|
| Operating Cash Flow | $20M | 35/58 |
| Free Cash Flow | $19M | 30/49 |
| Capital Spending | -$1M | 11/49 |
| OCF Growth YoY | -89.4% | 31/34 |
| FCF Growth YoY | -89.9% | 30/32 |
| FCF/Sales | 2.3% | 29/41 |
| CapEx/Sales | 0.1% | 37/41 |
Operational Efficiency
| Metric | SUPN | Rank |
|---|---|---|
| Asset Turnover | 0.58x | 15/39 |
| Receivables Turnover | 3.9x | 29/37 |
| Inventory Turnover | 0.9x | 27/35 |
| Fixed Assets Turnover | 81.4x | 11/40 |
| Days Sales Outstanding | 93 days | 9/37 |
| Days Inventory | 394 days | 9/35 |
| Payables Period | 21 days | 25/25 |
| Cash Conversion Cycle | 467 days | 3/23 |
Income Statement
| Metric | SUPN | Rank |
|---|---|---|
| Total Revenue | $830M | 32/45 |
| Operating Income | -$130M | 31/50 |
| Net Income | -$110M | 27/45 |
| R&D Expense | $126M | 53/57 |
| SG&A Expense | $561M | 32/40 |
| Cost of Goods Sold | $99M | 29/36 |
Dividend & Shareholder Information
| Metric | SUPN | Rank |
|---|---|---|
| Shares Outstanding | 58M | – |
| Net Income Growth | -270.1% | 19/19 |
| EPS Growth | -253.7% | 25/25 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $724M | 50.7% of assets |
| Cash & Short-term Investments | $180M | 12.6% of assets |
| Accounts Receivable | $212M | 14.8% of assets |
| Inventory | $107M | 7.5% of assets |
| Total Liabilities | $397M | 27.8% of assets |
| Short-term Debt | $342M | 23.9% of assets |
SUPN quarterly financials and insider trading
Supernus Pharmaceuticals, Inc. (SUPN) industry peers
Companies classified under the same SEC industry code as Supernus Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SUPN Supernus Pharmaceuticals, Inc. | ▶ | $2.30B |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $610.38B |
| ABBV Abbvie Inc. | ▶ | $500.75B |
| MRK Merck & Co., Inc. | ▲ | $358.21B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $258.35B |
| ABT Abbott Laboratories | ▼ | $182.04B |
| NVO Novo Nordisk A S | ▼ | $174.29B |
| PFE Pfizer Inc | ▶ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $123.73B |
| SNY Sanofi | ▼ | $99.33B |
| GSK Gsk Plc | ▼ | $98.90B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.32B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▲ | $24.33B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.67B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.94B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.92B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $13.12B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $12.26B |
| ELAN Elanco Animal Health Inc | ▼ | $11.76B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.85B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.62B |
| CYTK Cytokinetics Inc | ▲ | $8.89B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.47B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.26B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.33B |
| ABVX Abivax S.A. | ▼ | $7.26B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.73B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.24B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.15B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| BLTE Belite Bio, Inc | ▲ | $6.00B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.95B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.35B |
| ERAS Erasca, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.89B |
| MANE Veradermics, Inc | ▲ | $4.81B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.17B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.15B |
Where SUPN sits on the market map
Supernus Pharmaceuticals, Inc. (SUPN) stock news
Loading...
Supernus Pharmaceuticals, Inc. (SUPN) stock forecast FAQ
What is the Supernus Pharmaceuticals, Inc. (SUPN) stock forecast?
On Oct. 16, 2026, SUPN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5121 stocks scored that day.
How accurate are Supernus Pharmaceuticals, Inc. stock predictions?
For SUPN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Supernus Pharmaceuticals, Inc. forecasts updated?
Supernus Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Supernus Pharmaceuticals, Inc.'s industry peers?
60 issuers in our coverage, SUPN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.